z-logo
open-access-imgOpen Access
PAPSS2 Deficiency Causes Androgen Excess via Impaired DHEA Sulfation—In Vitro and in Vivo Studies in a Family Harboring Two Novel PAPSS2 Mutations
Author(s) -
Wilma Oostdijk,
Jan Idkowiak,
Jonathan Wolf Mueller,
Philip J House,
Angela E. Taylor,
Michael OʼReilly,
Beverly Hughes,
Martine C. de Vries,
Sarina G. Kant,
Gijs W.E. Santen,
Annemieke J.M.H. Verkerk,
André G. Uitterlinden,
Jan M. Wit,
Monique Losekoot,
Wiebke Arlt
Publication year - 2015
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2014-3556
Subject(s) - endocrinology , medicine , dehydroepiandrosterone , androgen , sulfation , dehydroepiandrosterone sulfate , adrenarche , sulfotransferase , biology , biochemistry , hormone
PAPSS2 (PAPS synthase 2) provides the universal sulfate donor PAPS (3'-phospho-adenosine-5'-phosphosulfate) to all human sulfotransferases, including SULT2A1, responsible for sulfation of the crucial androgen precursor dehydroepiandrosterone (DHEA). Impaired DHEA sulfation is thought to increase the conversion of DHEA toward active androgens, a proposition supported by the previous report of a girl with inactivating PAPSS2 mutations who presented with low serum DHEA sulfate and androgen excess, clinically manifesting with premature pubarche and early-onset polycystic ovary syndrome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom